Citation Tools

Download PDFPDF

710 Safety and survival results from a phase 1/2 trial of intratumoral agent INT230–6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers
Free

Download to a citation manager

Cite this article as:
Thomas J, El-Khoueiry A, Hanna D, et al
710 Safety and survival results from a phase 1/2 trial of intratumoral agent INT230–6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers